Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Heparin binds to antithrombin III (ATIII), accelerating its inhibition of thrombin (factor IIa) and factor Xa, thereby preventing fibrin clot formation.
Aminophylline is a complex of theophylline and ethylenediamine. Theophylline acts as a non-selective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, leading to bronchodilation. It also blocks adenosine receptors, stimulates catecholamine release, and enhances diaphragmatic contractility. The ethylenediamine component increases solubility.
Prophylaxis and treatment of venous thrombosis and pulmonary embolism,Atrial fibrillation with embolization,Treatment of acute coronary syndromes (unstable angina, NSTEMI, STEMI),Anticoagulation during cardiac/vascular surgery, hemodialysis, and extracorporeal circulation,Off-label: Prevention of recurrent miscarriage associated with antiphospholipid syndrome
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases (e.g., emphysema, chronic bronchitis),Adjunctive therapy in acute bronchial asthma and status asthmaticus,Off-label: Treatment of apnea of prematurity
Intravenous: Initial bolus of 5,000 units followed by continuous infusion of 13-21 units/kg/hour (typically 1,000-2,000 units/hour) titrated to a PTT 1.5-2.5 times control. Subcutaneous: 5,000 units every 8-12 hours for prophylaxis; 10,000-20,000 units every 12 hours for treatment.
Loading dose: 5-6 mg/kg IV over 20-30 minutes (if not on theophylline). Maintenance: 0.5-0.7 mg/kg/h IV continuous infusion.
Terminal elimination half-life: 1-2 hours (dose-dependent, saturable clearance); prolonged to 2-6 hours in renal impairment, obese patients, or with high doses; clinical anticoagulant effect may persist 2-4 hours after a single IV bolus.
Terminal elimination half-life: 3-12 hours in adults (mean 5-6 hours); prolonged in hepatic impairment, heart failure, COPD, and neonates (up to 30 hours). Smoking reduces half-life by 30-50%.
Heparin undergoes hepatic metabolism (desulfation) and is partially depolymerized; clearance is via reticuloendothelial system and renal excretion.
Theophylline is metabolized primarily in the liver by cytochrome P450 isoenzymes, predominantly CYP1A2, with minor contributions from CYP2E1 and CYP3A4. Metabolism involves N-demethylation and oxidation. In neonates, metabolism is immature; in adults, ~90% is hepatically cleared. Ethylenediamine is minimally metabolized.
Primarily renal (via reticuloendothelial system); 40-50% excreted unchanged in urine; 20-30% metabolized to uroheparin and excreted renally; minor biliary (<5%).
Renal excretion of unchanged drug (about 10-20%) and metabolites (primarily 1,3-dimethyluric acid, 1-methyluric acid, 3-methylxanthine). Billary/fecal excretion is negligible.
Heparin binds extensively to antithrombin III (AT-III) and multiple plasma proteins including histidine-rich glycoprotein, platelet factor 4, vitronectin, fibronectin, and lipoproteins; very high overall protein binding (nearly 100% to AT-III when bound, but free fraction varies due to competition).
Theophylline (active moiety): approximately 40% bound to plasma proteins, primarily albumin. Protein binding decreases in neonates, hepatic cirrhosis, and uremia.
Vd approximately 0.03-0.10 L/kg (largely confined to plasma volume; limited extravascular distribution); increased Vd in pregnancy, obesity, and nephrotic syndrome.
Apparent volume of distribution: approximately 0.4-0.6 L/kg (average 0.45 L/kg). Indicates distribution into total body water; slightly higher in neonates and premature infants.
SC: 80-93% relative to IV (due to first-pass hepatic metabolism and local degradation); IV: 100%.
Oral: 96-100% for immediate-release tablets; 50-70% for some sustained-release formulations depending on formulation. Rectal: 70-80% (variable). IV: 100%.
No specific dose adjustment for GFR; monitor a PTT closely in renal impairment (Cr Cl <30 m L/min) due to increased bleeding risk. For continuous infusion, consider lower initial rates (e.g., 13 units/kg/hour) and titrate carefully.
No dose adjustment required for GFR >30 m L/min. For GFR 10-30 m L/min: reduce maintenance dose by 50% and monitor serum theophylline levels. For GFR <10 m L/min: reduce maintenance dose by 50% and extend dosing interval or use with caution.
No established guidelines; use with caution in Child-Pugh B or C due to coagulopathy and decreased antithrombin III levels. Monitor a PTT more frequently.
Child-Pugh A: reduce dose by 50%. Child-Pugh B: reduce dose by 75%. Child-Pugh C: contraindicated or use with extreme caution, reduce dose by 80% and monitor levels.
Intravenous: Bolus 50-100 units/kg, then continuous infusion 15-25 units/kg/hour. Subcutaneous: 50-100 units/kg every 6-8 hours for prophylaxis; 100-150 units/kg every 6 hours for treatment. Titrate to age-appropriate a PTT (e.g., 60-85 seconds in neonates).
Loading dose: 1 mg/kg IV (if not on theophylline). Maintenance: Continuous infusion: age 6 months-1 year: 0.5 mg/kg/h; age 1-9 years: 0.8 mg/kg/h; age 9-12 years: 0.7 mg/kg/h; age 12-16 years: 0.6 mg/kg/h. Maximum daily dose: 24 mg/kg/day.
Lower initial doses (e.g., 50-70% of usual) with careful titration; increased risk of bleeding due to altered clearance. Monitor a PTT and renal function closely.
Consider lower initial doses due to decreased clearance. Use ideal body weight. Start at lower maintenance infusion rate (e.g., 0.3 mg/kg/h) and titrate based on serum levels and clinical response. Monitor for toxicity.
Spinal/epidural hematomas: Risk hemiparesis or paralysis with neuraxial anesthesia or spinal puncture, especially in patients on anticoagulants or with indwelling catheters.
None
Hemorrhage risk (monitor for bleeding; adjust dose based on a PTT),Heparin-induced thrombocytopenia (HIT) Type II (immune-mediated, monitor platelets),HIT Type I (non-immune thrombocytopenia),Hyperkalemia due to aldosterone suppression (risk in renal impairment, diabetes, or K+-sparing drugs),Heparin resistance (low ATIII levels),Osteoporosis with long-term use (>6 months)
Narrow therapeutic index; serum theophylline levels must be monitored to avoid toxicity. Risk of seizures, cardiac arrhythmias, and death, especially at high serum concentrations. Caution in patients with hepatic impairment, congestive heart failure, cor pulmonale, fever, and in the elderly. Drug interactions with cimetidine, fluoroquinolones, macrolides, oral contraceptives, and other CYP1A2 inhibitors can increase toxicity.
Severe thrombocytopenia (including HIT),Active major bleeding or bleeding diathesis (e.g., hemophilia, severe liver disease),Hypersensitivity to heparin or pork products,History of HIT or HIT with thrombosis,Use for spinal/epidural anesthesia in patients with indwelling epidural catheter (relative to black box warning),Severe uncontrolled hypertension or recent brain/spinal cord surgery (relative)
Absolute: Hypersensitivity to theophylline, ethylenediamine, or any component; use in patients with active seizure disorder (unless receiving appropriate anticonvulsant therapy); use in patients with a history of ventricular arrhythmias (except under close supervision). Relative: Peptic ulcer disease, hyperthyroidism, hypertension, and renal impairment.
No specific food interactions. However, vitamin K-rich foods (e.g., leafy greens) may antagonize effects if given with warfarin; heparin effect is not vitamin K-dependent.
Avoid large amounts of caffeine-containing foods and beverages (coffee, tea, cola, chocolate) as they can potentiate theophylline effects and increase risk of toxicity. A high-protein diet may increase theophylline clearance; maintain consistent dietary habits.
Pregnancy category C. Heparin does not cross the placenta; no risk of fetal teratogenesis. However, increased risk of maternal bleeding, which may indirectly affect fetal well-being. Use only if clearly needed.
Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity but some developmental delays at high doses. Second and third trimesters: Use only if benefit outweighs risk; may cause fetal tachycardia or irritability due to adenosine receptor blockade. Avoid near term due to potential neonatal irritability.
Heparin is not excreted into breast milk due to high molecular weight and protein binding; M/P ratio not applicable. Considered compatible with breastfeeding.
Not recommended unless essential. Aminophylline is excreted into breast milk; M/P ratio approximately 0.6–0.8. Monitor infant for irritability or insomnia. Consider alternative therapies if breastfeeding.
Pregnancy increases volume of distribution and clearance, leading to lower plasma heparin levels. Dose adjustments may be needed to maintain therapeutic a PTT/anti-Xa levels; more frequent monitoring recommended.
Pregnancy may decrease protein binding and increase clearance of theophylline; monitor serum levels closely. Dose may need to be increased by 10–30% to maintain therapeutic levels. Postpartum, doses may need reduction.
Heparin is an anticoagulant used for prophylaxis and treatment of thromboembolic disorders. Monitor a PTT closely; therapeutic range typically 1.5-2.5 times control. Avoid intramuscular administration due to risk of hematoma. Use with caution in renal impairment. Protamine sulfate is the antidote for heparin overdose.
Aminophylline is a bronchodilator used primarily for asthma and COPD exacerbations. Monitor serum theophylline levels closely due to narrow therapeutic index (10-20 mcg/m L). Administer IV infusion over 30 minutes to avoid hypotension. Caution in patients with cardiac arrhythmias, hyperthyroidism, or seizure disorders. Drug interactions include cimetidine, fluoroquinolones, and macrolides which increase theophylline levels.
Do not take aspirin or NSAIDs unless prescribed by your doctor, as they increase bleeding risk.,Report any unusual bleeding, bruising, or dark stools immediately.,Use a soft toothbrush and electric razor to avoid cuts.,Keep all appointments for blood tests to monitor your therapy.,Wear a medical alert bracelet indicating you are on heparin.
Take this medication exactly as prescribed; do not stop or change dose without consulting your doctor.,Avoid excessive caffeine intake (coffee, tea, chocolate, cola) as it may increase side effects like jitteriness and palpitations.,Report any symptoms of toxicity such as nausea, vomiting, insomnia, rapid heart rate, or seizures immediately.,Inform your healthcare provider of all other medications, especially antibiotics, heart medications, or seizure drugs.,Do not chew or crush the solution; it is for intravenous use only under medical supervision.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, answered by our medical review team.
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is a Electrolyte that works by Heparin binds to antithrombin III (ATIII), accelerating its inhibition of thrombin (factor IIa) and factor Xa, thereby preventing fibrin clot formation.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine. Theophylline acts as a non-selective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, leading to bronchodilation. It also blocks adenosine receptors, stimulates catecholamine release, and enhances diaphragmatic contractility. The ethylenediamine component increases solubility.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is: Intravenous: Initial bolus of 5,000 units followed by continuous infusion of 13-21 units/kg/hour (typically 1,000-2,000 units/hour) titrated to a PTT 1.5-2.5 times control. Subcutaneous: 5,000 units every 8-12 hours for prophylaxis; 10,000-20,000 units every 12 hours for treatment.. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is: Loading dose: 5-6 mg/kg IV over 20-30 minutes (if not on theophylline). Maintenance: 0.5-0.7 mg/kg/h IV continuous infusion.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is classified as Category A/B. Pregnancy category C. Heparin does not cross the placenta; no risk of fetal teratogenesis. However, increased risk of maternal bleeding, which may indirectly affect fetal well-bein. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is classified as Category A/B. Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity but some developmental delays at high doses. Second and third trimesters: Use only . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.